The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Valeant Pharmaceuticals International Inc

TSX: VRX
Delayed quote

$14.44

Today's change-0.09 -0.62%
Updated March 24 10:12 AM EDT. Delayed by at least 15 minutes.
 

Valeant Pharmaceuticals International Inc

TSX: VRX
Delayed quote

$14.44

Today's change-0.09 -0.62%
Updated March 24 10:12 AM EDT. Delayed by at least 15 minutes.

Valeant Pharmaceuticals International Inc down $0.09

Valeant Pharmaceuticals International Inc is lower today, dropping $0.09 or 0.62% to $14.44. Over the last five days, shares have lost 1.90% and sit 4.49% above their 52-week low. This security has underperformed the S&P TSX by 80.69% during the last year.

Key company metrics

  • Trailing P/ENegative, not meaningful
  • P/E 1 year forward2.53×
  • Forward PEG0.12×
  • Indicated annual dividend--
  • Dividend yield--
  • Trailing EPS-$9.23
Updated March 24 10:12 AM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-24.89%

Although this company's net profit margin is negative, it is above the industry average and implies that Valeant Pharmaceuticals International Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.17%Sector:HealthcareIndustry:Pharmaceuticals - Diversified

Latest Company News

View more News

Latest Press Releases

View more Press Releases
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2016Q3/2016Q2/2016Q1/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201612/31/2016Sep 30, 201609/30/2016Jun 30, 201606/30/2016Mar 31, 201603/31/2016
Revenue2,4032,4802,4202,372
Total other revenue--------
Total revenue2,4032,4802,4202,372
Gross profit1,7371,8221,7621,742
Total cost of revenue665658658630
Total operating expense2,2523,3432,3402,305
Selling / general / administrative665661672813
Research & development93101124103
Depreciation / amortization284807888695
Interest expense (income), net operating--------
Unusual expense (income)4531,1154442
Other operating expenses, total931-4523
Operating income150-8638166
Interest income (expense), net non-operating-467-470-473-427
Gain (loss) on sale of assets--------
Other--------
Income before tax-360-1,332-377-366
Income after tax-512-1,219-304-373
Income tax, total152-113-737
Net income-515-1,218-302-374
Total adjustments to net income--------
Net income before extra. items-515-1,218-302-374
Minority interest-312-1
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-515-1,218-302-374
Inc. avail. to common incl. extra. items-515-1,218-302-374
Diluted net income-515-1,218-302-374
Dilution adjustment----0--
Diluted weighted average shares350350345345
Diluted EPS excluding extraordinary itemsvalue per share-1.47-3.49-0.88-1.08
Dividends per sharevalue per share--0.000.000.00
Diluted normalized EPSvalue per share-0.64-1.38-0.78-1.00